BEST-J score 17+
Yoichi Kakuta
iPhone용으로 디자인됨
-
- 무료
iPhone 스크린샷
설명
Bleeding after ESD occurs in 4.1%–8.5% of patients who undergo gastric ESD. The "BEST-J score" is a prediction model to stratify the risk of bleeding after ESD for early gastric cancers. Nine factors were weighted with point values: 4 points for anticoagulants (warfarin, direct oral anticoagulants), 3 points for chronic kidney disease with hemodialysis, 2 points each for P2Y12 receptor antagonist (thienopyridine) and aspirin, 1 point each for cilostazol, a tumor size >30 mm, lower-third in tumor location, and presence of multiple tumors, and −1 point for interruption of each kind of antithrombotic agents. The patients were categorized into four bleeding risk groups: low (0–1 points: 2.8% risk), intermediate (2 points: 6.1%), high (3–4 points: 11.4%) and very high (≥5 points: 29.7%).
*1. If an antiplatelet agent was replaced with another agent, select "Temporal discontinuation" of the original agent and "None" of the replaced agent. For example, if P2Y12 receptor antagonist is replaced with aspirin, select "Temporal discontinuation" of P2Y12 receptor antagonist and "None" of aspirin.
*2. If the patient received heparin bridging therapy, select "Temporal discontinuation" of the original agent. For example, if warfarin is bridged with heparin, select "Temporal discontinuation" of warfarin.
*3. Time of discontinuing antithrombotic agents before ESD is based on the Japanese guidelines (Dig Endosc. 2014; 26: 1-14.): aspirin, 3−5 days; P2Y12 receptor antagonist (thienopyridine), 5−7 days; cilostazol, 1 day; warfarin, 3−5 days; DOAC, 1−2 days.
For more information, see the reference below.
Gut. 2020 [Epub ahead of print]
A prediction model of bleeding after endoscopic submucosal dissection for early gastric cancer: BEST-J score.
Hatta W, Tsuji Y, Yoshio T, Kakushima N, Hoteya S, Doyama H, Nagami Y, Hikichi T, Kobayashi M, Morita Y, Sumiyoshi T, Iguchi M, Tomida H, Inoue T, Koike T, Mikami T, Hasatani K, Nishikawa J, Matsumura T, Nebiki H, Nakamatsu D, Ohnita K, Suzuki H, Ueyama H, Hayashi Y, Sugimoto M, Yamaguchi S, Michida T, Yada T, Asahina Y, Narasaka T, Kuribayashi S, Kiyotoki S, Mabe K, Nakamura T, Nakaya N, Fujishiro M, Masamune A.
You can view the application help by tapping a title bar.
DISCLAIMER: This application is intended for educational or research purposes only. It does not create any patient-physician relationship, and should not be used as a substitute for professional diagnosis and treatment.
[Developer]
2020 東北大学病院消化器内科・大腸グループ
2020 Kenichi Negoro, MD, PhD
2020 Yoichi Kakuta, MD, PhD
2020 Waku Hatta, MD, PhD (Consultant)
2020 Xiaoyi Jin, MD, PhD (Translation)
http://www.gastroente.med.tohoku.ac.jp/
tohoku.ibd@gmail.com
앱이 수집하는 개인정보
Yoichi Kakuta 개발자가 개인정보 처리방침 및 데이터 처리 방식에 관한 세부사항을 Apple에 제공하지 않았습니다. 자세한 내용은 개발자의 개인정보 처리방침을 참조하십시오.
세부사항이 제공되지 않음
개발자가 다음번에 앱 업데이트를 제출할 때 개인정보 보호 세부사항을 제공해야 합니다.
정보
- 제공자
- Yoichi Kakuta
- 크기
- 832.5KB
- 카테고리
- 건강 및 피트니스
- 호환성
-
- iPhone
- iOS 13.1 이상 필요.
- iPod touch
- iOS 13.1 이상 필요.
- Mac
- macOS 11.0 이상 및 Apple M1 칩 이상이 탑재된 Mac이 필요.
- Apple Vision
- visionOS 1.0 이상 필요.
- 언어
-
영어, 일본어, 중국어(간체)
- 연령 등급
- 17+ 상습적인/과격한 의료/치료 정보
- 저작권
- © 2020 Yoichi Kakuta and Kenichi Negoro
- 가격
- 무료